Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$0.49
-2.0%
C$0.52
C$0.45
C$0.69
C$8.93M1.6915,150 shs27,543 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
-2.02%-1.02%-6.73%-13.39%-6.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$16.62M0.54C$0.40 per share1.20C$0.83 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
-C$2.61M-C$0.15N/AN/A-15.73%-15.60%-8.26%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
5.77
2.70
2.29

Institutional Ownership

CompanyInstitutional Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
10.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
6218.41 millionN/ANot Optionable

Recent News About These Companies

Crescita Therapeutics Inc. (CTX.TO) - Yahoo Finance
Crescita Reports First Quarter 2025 Results
Crescita Reports First Quarter 2025 Results
Crescita Reports Q4 and Fiscal 2024 Results
Crescita Therapeutics Inc. (CRRTF)
Chordia Therapeutics Advances Cancer Drug Development
Compass Therapeutics presents biomarker data related to CTX-471
Crescita Reports Third Quarter 2024 Results
Crescita Reports Second Quarter 2024 Results
Closing Bell: Crescita Therapeutics Inc up on Monday (CTX)
Crescita Therapeutics stock logo

Crescita Therapeutics TSE:CTX

C$0.48 -0.01 (-2.02%)
As of 07/2/2025 11:28 AM Eastern

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.